Genetech eye treatment receives FDA approval
In January 2022, Genetech Inc (Genetech) announced that the U.S. Food and Drug Administration (FDA) had approved Vabysmo, the first bispecific eye antibody that treats wet or neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). AMD and DME are the two leading causes of vision loss among adults in the US. Vabysmo is the only injectable medication approved to treat both wet AMD and DME, providing patients with flexibility based on their needs.
Balance Sheet|Competition|M&AIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.